BBK has been selected as a finalist for the 2022 Pharmaceutical Executive APEX Awards — the only healthcare marketing awards judged entirely by HCPs. We are among five finalists for the Central Nervous System — Disease Awareness / Education (Unregulated) category. Our creative specialist are being recognized for the Cerevel TemPo Studies website — a website developed to inform and prescreen patients newly diagnosed with Parkinson’s disease.
"We are honored to be recognized by healthcare professionals who understand what it takes to build trust in the Parkinson's disease community," said Mike Schaeffer, BBK's creative director. "At BBK, we take great pride in our patient-centric approach, embracing the patient and caregiver perspectives to ensure that our clinical trial outreach resonates with potential participants."
The TemPo Studies website and the recruitment campaign took a sympathetic tone with the understanding that patients recently diagnosed, along with their loved ones, are looking to make the most of their time and quality of life in the face of this progressive disease. The TemPo studies evaluated the oral investigational drug tavapadon to see if it may help improve Parkinson’s disease symptoms that impact movement and daily activities.